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Abstract
The virulence factor pertactin (Prn) is a component of pertussis vaccines and one of the most polymorphic Bordetella
pertussis antigens. After the introduction of vaccination shifts in predominant Prn types were observed and strains with the
Prn vaccine type (Prn1) were replaced by strains carrying non-vaccine types (Prn2 and Prn3), suggesting vaccine-driven
selection. The aim of this study was to elucidate the shifts observed in Prn variants. We show that, although Prn2 and Prn3
circulated in similar frequencies in the 1970s and 1980s, in the 1990s Prn2 strains expanded and Prn3 strains disappeared,
suggesting that in vaccinated populations Prn2 strains are fitter than Prn3 strains. We established a role for Prn in the mouse
model by showing that a Prn knock-out (Prn-ko) mutation reduced colonization in trachea and lungs. Restoration of the
mutation resulted in a significant increase in colonization compared to the knock-out mutant. The ability of clinical isolates
with different Prn variants to colonize the mouse lung was compared. Although these isolates were also polymorphic at
other loci, only variation in the promoter for pertussis toxin (ptxP) and Prn were found to contribute significantly to
differences in colonization. Analysis of a subset of strains with the same ptxP allele revealed that the ability to colonize mice
decreased in the order Prn1.Prn2 and Prn3. Our results are consistent with the predominance of Prn1 strains in
unvaccinated populations. Our results show that ability to colonize mice is practically the same for Prn2 and Prn3. Therefore
other factors may have contributed to the predominance of Prn2 in vaccinated populations. The mouse model may be
useful to assess and predict changes in the B. pertussis population due to vaccination.
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Introduction
Bordetella pertussis causes whooping cough or pertussis, a
respiratory disease that is most severe in infants. Before childhood
vaccination was introduced in the 1950s, pertussis was a major
cause of infant mortality worldwide. Whole cell vaccines against
pertussis were introduced in the 1940s to 1960s and these were
replaced by more defined and less reactogenic acellular vaccines
(ACVs) in the 1990s [1,2]. All ACVs contain pertussis toxin (Ptx).
In addition, they may contain filamentous hemagglutinin (FHA),
pertactin (Prn) and serotype 2 and 3 fimbriae. Widespread
vaccination of children significantly reduced morbidity and
mortality. However, in the 1990s a resurgence of pertussis was
observed in countries with highly vaccinated populations and
pertussis has become the most prevalent vaccine preventable
disease in developed countries [2,3]. Although morbidity is highest
in newly born, pertussis is now recognized as a frequent infection
of adults [4,5].
The re-emergence of pertussis has been attributed to waning
vaccine-induced immunity and pathogen adaptation [3,6].
Pathogen adaptation is supported by several observations.
Antigenic divergence has occurred between vaccine strains and
clinical isolates with respect to several vaccine components; Ptx,
Prn, and fimbriae [3,6,7,8]. Further variation in Ptx and Prn has
been shown to affect vaccine efficacy in a mouse model
[9,10,11,12,13]. In addition to antigenic variation, increased Ptx
production has been associated with the resurgence of pertussis
[14]. Strains with a novel allele for the Ptx promoter (ptxP3)
emerged in the 1990s, replacing the resident ptxP1 strains. A role
of vaccination in driving shifts in B. pertussis populations is also
supported by recent genomic data [15,16].
Prn, the focus of this study, is one of the most polymorphic B.
pertussis proteins known and 13 prn alleles have been identified so
far [3,6]. Variation in Prn is mainly limited to two regions,
designated R1 and R2, which are comprised of Gly-Gly-X-X-Pro
and Pro-Gln-Pro repeats, respectively. The R1 region is located
proximal to a RGD motif implicated in receptor binding
[17] (Fig. 1A). Studies in a number of countries have reveal-
ed similar temporal trends in the frequency of Prn variants
[8,10,18,19,20,21,22,23,24,25,26,27,28]. In the last fifty years
three Prn variants have been found to predominate: Prn1, Prn2
and to a lesser extent Prn3. In the prevaccination era, essentially
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30 years after the introduction of whole cell vaccination, Prn
strains were replaced by Prn2 and Prn3 strains. As most vaccines
contain Prn1 it was suggested that the emergence of Prn2 and
Prn3 was vaccine-driven [8]. Consistent with this assumption, it
was found that a whole cell vaccine containing Prn1 was less
effective against Prn2 strains compared to Prn1 strains in a mouse
model [13]. Prn2 strains now predominate in most vaccinated
populations. Njamkepo et al. [29] have analyzed strains from a
region in Senegal where vaccination was introduced only recently
(and where the coverage was still low). They found that, in contrast
to strains isolated in the same period in France (where vaccination
was introduced in the 1950s and where vaccination coverage is
high), all Senegalese strains carried the prn1 allele, characteristic
for prevaccination strains. This observation is consistent with the
theory of vaccine-driven shifts. Other arguments for the role of
vaccination in shifts of Prn variants have recently been reviewed
[3]. In the 1990s, whole cell vaccines were replaced by acellular
vaccines. Sporadically, in the acellular vaccine period, strains have
been isolated which do not produce Prn [30]. However, recently in
France a significant percentage (5.6%) of the strains isolated from
hospitalized children did not produce pertactin [31]. It was found
that the Prn gene was inactivated by deletion or insertion of IS481
[31]. Spread of such Prn-knock out strains may reduce vaccine
efficacy, in particular of acellular vaccines which induce a less
broad immunity than whole cell vaccines. Evaluation of this threat
is hampered by our lack of understanding of the role Prn plays in
the ecology of B. pertussis. Here we compare the ability of a Prn-
knock out strain with a wild type strain to colonize the mouse lungs
and trachea. We also assess the effect of variation in R1 of Prn on
colonization in this model.
Methods
Bacterial strains
B. pertussis strains were isolated from Dutch patients in the
period 1949 to 1996. Strains were grown on Bordet-Gengou agar
(Difco Catalogue no. 0048-17-5) supplemented with 1% (v/v)
glycerol and 15% (v/v) sheep blood at 35 uC for 3 days. Strains
were made streptomycin resistant to allow recovery on selective
plates from mouse lungs and trachea. Characteristics of the strains
used are shown in Table S1. Tohama I derivatives were used to
construct Prn mutants [32] (Table 1).
Construction of Prn knock-out mutants
To construct a Prn knockout mutant (Prn-ko), a fragment of prn
(469 bases in size) was amplified using primers PrnXba1F (GCT-
CTAGAGCCTGGCATCCAATGAACATGT) and PrnEcoR1R
(GGAATTCCTGTTCGCCGGCCACATAG), and cloned into
pSS1129 [33], resulting in pSR2.1. Subsequently, a kanamycin
resistance gene cassette was cloned into the RsrII site located in
the 469 base prn fragment of pSR2.1, resulting in pSR2-1.1. The
latter plasmid was used to introduce the kan gene into prn1 of the
Tohama I derivative B213 by allelic exchange [34]. Correct
insertion was checked by sequencing and one strain, B1686, was
selected for further studies. Expression of Prn in the knock-out
mutant was restored by allelic exchange using pSR2.1. Back
mutants were identified by PCR and DNA sequencing. One clone,
Figure 1. Variation in pertactin (A) and temporal trends in the frequency of pertactin alleles (B). The number in the pertactin sequences
indicates the amino acid position relative to the N-terminus. The RGD motif implicated in binding to host receptors has been underlined. Repeat
motifs are blocked. Dots and dashes indicate sequence identity with Prn1 and gaps, respectively. No strains were available from the period 1960-1964
to determine allele frequencies. Vaccination against pertussis was introduced in 1953.
doi:10.1371/journal.pone.0018014.g001
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Prn by B213 and its derivatives was assessed by immunoblotting.
Strain typing
Genotyping was focused on the following genes essentially as
described in [35,36]: prn, ptxP, ptxA and tcfA, coding for,
respectively, Prn, the Ptx promoter, the Ptx S1 subunit, and the
tracheal colonization factor. Typing of prn alleles is done by
sequencing of the repeat regions 1 and 2, and does not distinguish
between prn1 and prn7 which are identical in region 1 and 2 but
differ in a non-silent SNP outside these regions. Whole genome
sequencing has revealed that prn7 is associated with strains which
only circulated in the 1950s and 1960s and we assumed here that
all strains harbored prn1. Serotyping, which distinguishes between
strains producing type 2 or type 3 fimbriae (Fim2 or Fim3) was
carried out using the slide agglutination technique [37].
Mouse infection model
All animal was conducted according to relevant national and
international guidelines. Strains were grown on Bordet-Gengou
plates at 35uC for 24 hrs. After harvesting, the bacterial
concentration was adjusted to 5610
9 bacteria/ml. The bacterial
suspensions were flash-frozen in ethanol/dry ice in small aliquots
in Verwey medium [38] with 15% glycerol and stored at –80uC.
The viability of the frozen cell suspensions was determined prior to
infection. For infection, eight BALB/c mice (Harlan, OlHsd) 4–5
weeks old, were lightly anaesthetised with isoflurane and 40 mlo f
the inoculum, containing 2*10
7 CFUs bacteria, was placed on the
nostrils and allowed to be inhaled. Three days after infection, mice
were sacrificed by intraperitoneal injection of Nembutal
R (Sanofi/
Algrin). To recover B. pertussis, trachea and lungs were removed.
The trachea was vortexed in 500 ml Verwey medium with 5 glass
pearls for 30 sec at RT. Lungs were homogenised in 900 ml
Verwey medium for 10 sec at 20,000 rpm with a homogenizer
(Pro Scientific, Pro200) at RT. Appropriate dilutions were plated
on Bordet-Gengou plates supplemented with streptomycin, and
the number of CFUs was determined. All animal experiments
were approved by the Institute’s Animal Ethics Committee.
Statistical analysis
CFU counts recovered from mice were log-transformed and
zero counts were considered missing values. The data were
analysed by Proc GLM in SAS 9.1 (SAS Institute Inc., Cary, NC,
USA). The significance among means was tested by the Student-
Newman-Keuls test at alpha =0.01 or 0.05. Strengths of effects of
variation in fimbrial serotype, Prn, the Ptx promoter (ptxP), the Ptx
S1 subunit (PtxA) and TcfA on colonization were assessed by
ANOVA, followed by a Tukey post-test (Tukey Honest Significant
Differences). The ANOVA table can be found in the supporting
information section (Table S2). Based on this information, the
effect of variation in Prn was assessed in a subset of strains which
harbored the same ptxP allele, ptxP1.
Results
Temporal trends in prn alleles in the Netherlands
In a previous work, we analyzed the frequencies of Prn variants
in the Netherlands between 1949 and 1996 [8]. Here we extended
this analysis to 2009 and included more strains. Pertussis
vaccination in the Netherlands was introduced in 1953. The
strain composition of the whole cell vaccine was changed a few
times, but remained the same from the early 1960s on, when it was
comprised of two strains producing Prn1 and Prn7. Prn1 and Prn7
are identical, except for a single amino acid substitution outside
the two repeat regions [3]. In the period 1949–1975, Prn1 strains
predominated, representing 97% of the isolates (N 64) (Fig. 1B). In
this period only two other Prn variants were observed, each in a
single strain, Prn2 in 1950 and Prn10 in 1954. In the period 1976–
1985, Prn2 and Prn3 strains emerged. Initially, frequencies of both
Prn2 and Prn3 strains increased with similar rates. However, in
the mid 1990s Prn3 strains decreased in frequency, while Prn2
strains continued to expand. Since 2003, only Prn2 strains have
been detected in the Netherlands (N 203). These data suggest that
Prn1 strains are more fit in unvaccinated populations, while the
non-vaccine types, Prn2 and Prn3, strain are more fit in
vaccinated populations. However, of the two non-vaccine types,
Prn2 seemed to confer the greatest increase in fitness in vaccinated
populations.
The effect of inactivation of the prn gene on colonization
of the mouse respiratory tract
In a next step we aimed to determine the effect of variation in
Prn on colonization of the mouse respiratory tract. However, it
was not clear whether Prn played any role in this animal model.
To investigate this, mice were infected with the Tohama I strain or
a derivative in which the Prn gene was inactivated by insertion of a
kanamycin resistant gene cassette (Prn-ko strain). Subsequently,
colonization was assessed three days after infection (Fig. 2). The
Prn-ko mutation reduced colonization in trachea and lungs 6- and
4-fold, respectively (P,0.01). When the wild type phenotype was
Table 1. Characteristics of strains used in this study
1.
Tohama I derivatives
Strain designation: Genotype: Remarks: Reference:
B0213 ptxP1, ptxA2, tcfA2, prn1, Fim2 Strep resistant Tohama I derivative [48]
B1686 ptxP1, ptxA2, tcfA2, prn::kan, Fim2 Prn knock out derived from B0213 This work
B2576 ptxP1, ptxA2, tcfA2, prn1, Fim2 Back mutant derived from B1686 This work
Vaccine strains
Strain designation: Genotype: Remarks: Reference:
Strain 134 ptxP1, ptxA2, tcfA2, prn1, Fim2,3 Used for the Dutch whole-cell vaccine [3]
Strain 509 ptxP1, ptxA4, tcfA2, prn7, Fim2,3 Used for the Dutch whole-cell vaccine [3]
1Alleles for ptxP, ptxA, tcfA and prn are shown in addition to the fimbrial (Fim) serotype produced. A table with clinical isolates is provided (Table S1).
doi:10.1371/journal.pone.0018014.t001
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trachea and lungs was restored (Fig. 2). Although the back mutant
showed slightly lower colonization levels compared to the wild
type strain in trachea and lungs, the difference was not statistically
significant. In contrast, the back mutation significantly increased
colonization compared to the knock-out mutant in trachea and
lungs (P,0.01).
The effect of natural variation in Prn on colonization of
the mouse lung
To investigate the effect of natural variation in Prn on
colonization, mice were infected with clinical isolates producing
one of the three predominant Prn variants, Prn1, Prn2 or Prn3.
Colonization of lungs was assessed three days post infection. A
comparison of the colonizing ability of Prn variants was
complicated by the fact that, in addition to Prn, the strains
showed variation in a number of other surface proteins such as
PtxA, TcfA and fimbriae (Table S1). Further, strains also differed
with respect to the pertussis toxin promoter, ptxP. Three ptxP
alleles (ptxP1, ptxP2 and ptxP3) were present in this collection of
strains. We have shown that ptxP3 strains produce more Ptx than
ptxP1 [14] and Ptx has been shown to affect the colonization of
naı ¨ve mice [39]. Thus any effect observed in mice could be due to
one or more of these polymorphic loci. Multivariate analyses
revealed that only variation in Prn and ptxP significantly affected
colonization of the mouse (P 0.007 and 0.024, respectively). Based
on this information, the effect of variation in Prn was assessed in a
subset of strains which harbored the same ptxP allele, ptxP1. Only
ptxP1 strains were used in these experiments because the changes
observed in Prn types occurred in a period when most strains
carried the ptxP1 allele. It was found that the ability of the strains
to colonize the mouse lung decreased in the order
Prn1.Prn2.Prn3 (Fig. 3). Only the difference between Prn1
and Prn2 was significant, however.
Discussion
The role Prn plays in the ecology of B. pertussis is still under
investigation. Prn is non-covalently attached to the outer
membrane and may play a role in adherence to monocytes and
other host cells [17,40]. Further, Prn may affect the host immune
response as it has been shown that it can augment the suppressive
effect of FHA on LPS-induced IL-12 production in vitro [41]. The
role of Prn in colonization of the mouse respiratory tract has been
studied with B. pertussis and the closely related species Bordetella
bronchiseptica. Nicholson and coworkers [42], used a swine isolate of
B. bronchiseptica to study the contribution of FHA and Prn to
respiratory disease in swine. They found that colonization of the
FHA-knock out (FHA-ko) mutant was lower than that of the wild
type in the nasal cavity, trachea and lungs. Further, the FHA-ko
mutant caused limited to no disease. In contrast, the Prn-ko
mutant caused similar disease severity relative to the wild type,
however, colonization of the Prn mutant was reduced relative to
the wild type during early and late infection. Inatsuka and
coworkers, studied the role of Prn in both rats and mice [43]. They
observed that, while a Prn-ko B. bronchiseptica strain did not differ
from a wild type strain in its ability to establish respiratory
infection in rats, it was cleared much faster than wild type bacteria
from the mouse lung. These authors went on to show that Prn
allows B. bronchiseptica to resist neutrophil-mediated clearance.
Studies with B. pertussis gave less clear results with respect to the
role of Prn. Roberts and coworkers [44] concluded that a Prn
mutant was able to colonize and grow in the lungs and trachea of
mice as well as the parent strain, BBC26, although it reached
slightly lower levels in both organs. In contrast, in two other
studies no effect of a Prn mutation on colonization of the mouse
lung was found [45,46]. Overall, these results suggested that the
role of Prn in colonization of the mouse was subtle.
In this study, inactivation of the Prn gene significantly reduced
colonization of both the trachea and lungs of mice (Fig. 2). Back
mutation restored the colonization ability. When clinical isolates
were tested for their ability to colonize the mouse lung, significant
differences were found. The clinical isolates differ at several other
loci making it difficult to assign phenotypes to particular
polymorphisms. Multivariate analyses indicated that only variation
in ptxP and Prn contributed significantly to the differences in
colonization. Ptx enhances colonization of the mouse respiratory
tract, presumably by suppressing host innate immunity [39]. Thus
the effect of ptxP on colonization is probably due to different levels
of Ptx produced in vivo, consistent with in vitro data [14]. When
strains were compared which carried an identical ptxP allele
(ptxP1), it was observed that the ability to colonize mice decreased
in the order Prn1.Prn2 and Prn3 (Fig. 3). This may be due to
differential binding of Prn variants to host receptors, as the
Figure 2. Role of Prn in colonization of the mouse respiratory
tract. Mice were infected intranasally with the Tohama I strain (wt), a
mutant derivative in which the Prn was inactivated (ko), or a back-
mutant in which the Prn gene was restored. Three days post-infection,
CFUs were determined in trachea and lungs. The experiment was
performed twice, and pooled data from both experiments are shown.
Error bars and asterisks indicate 95% confidence intervals and
significant differences (P,0.01), respectively.
doi:10.1371/journal.pone.0018014.g002
Figure 3. Effect of variation in Prn on colonization of the
mouse lung. Mice were infected with clinical isolates producing Prn1
(N=15), Prn2 (N=5) or Prn3 (N=8). Three days after infection, the
number of CFUs in the lung was determined. Error bars and asterisks
indicate 95% confidence intervals and significant differences (P,0.05),
respectively.
doi:10.1371/journal.pone.0018014.g003
B. pertussis: Studies on Prn Variation
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18014variable region is located close to the RGD sequence implicated in
attachment [17,47] (Fig. 1A).
The effect of variation in Prn on colonization of mice lungs
shows interesting parallels with epidemiological data. In the
prevaccination era, essentially all strains analyzed produced Prn1.
Prn2 and Prn3 emerged in the 1980s, 20 to 30 years after the
introduction of vaccination and although the frequency of the two
variants was initially similar, Prn2 is now by far the most
predominant type. Coexistence of Prn1, Prn2 and Prn3 strains in
vaccinated populations has also been observed in Finland, Sweden
and the UK [28,48,49,50]. Invariably, Prn2 strains rose to
predominance. These data suggest that Prn1 strains are more fit in
unvaccinated populations, while the non-vaccine types, Prn2 and
Prn3, strain are more fit in vaccinated populations. However, of
the two non-vaccine types, Prn2 seemed to confer the greatest
increase in fitness in vaccinated populations.
Taking together, based on our results and those on vaccinated
mice previously published [9,10,11,12,13] we propose that of the
three Prn variants, Prn1 binds most efficiently to the host cells,
explaining its predominance in unvaccinated populations. Vacci-
nation with Prn1-containing vaccines may have shifted the
competitive balance between Prn variants allowing non-vaccine
types Prn2 and Prn3 to emerge. Regarding Prn2 strains, it is not so
clear that they colonized more efficiently than Prn3 strains;
however, other factors may have contributed to the predominance
of Prn2 strains in vaccinated populations. E.g. it is conceivable that
antibodies induced by Prn1 bind less well to Prn2 compared to
Prn3. Indeed the Dutch WCV was shown to be less efficacious in
the mouse model against Prn2 strains compared to Prn3 strains,
although the difference was not statistically significant [13]. In
addition to Prn1, Prn2 and Prn3, 10 other Prn types have been
found in low frequencies in a number of countries [3]. We
speculate that the frequency of these variants is the compound
effect of receptor fit and cross immunity with vaccine-induced Prn
antibodies.
The effect of the Prn-KO mutation in the mouse model was
relatively small, and one should be careful in extrapolating these
results to human populations. Continued strain surveillance in
human populations is required to address the question whether
Prn-ko mutants which have emerged in France [31] are less fit in
human populations and will have a limited ability to spread or
cause disease compared to wild type strains. The B. pertussis
genome contains many silent genes with unknown function [32]
and it is conceivable that compensatory mutations may occur in
Prn-ko mutants by gene reactivation or by other mechanisms.
In addition to variation in Prn, variation in ptxP was found to
significantly affect colonization of the mouse respiratory tract. The
long term effect of vaccination on pathogen populations generally
cannot be evaluated in the relatively short period in which clinical
trials take place. Our results suggest that the mouse model can be
used to explain and predict changes in the B. pertussis population
due to vaccination.
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